Identity {#S1}
========

Other names: {#S2}
------------

FANCU

HGNC (Hugo): {#S3}
------------

XRCC2

Location: {#S4}
---------

7q36.1

Local order {#S5}
-----------

As outlined by NCBI (Gene), coding genes located most proximal to XRCC2 on 16p12.2, in the centromeric to telomeric direction, are GALNTL5 (polypeptide N-acetylgalactosaminyltranserase like 5), GALNT11 (polypeptide N-acetylgalactosaminyltransferase 11), KMT2C (lysine methyltransferase 2C), XRCC2, ACTR3B (ARP3 actin related protein 3 B homolog B), DPP6 (dipeptidyl peptidase like 6), and LOC107984014.

DNA/RNA {#S6}
=======

In a screen for X-ray sensitive cellular mutants in Chinese hamster ovary (CHO) cells, the irs1 clone, which was thought to be deficient in a novel DNA repair gene, was obtained ([@R15]).

Two groups subsequently mapped the region containing the defective gene to 7q36.1 in humans based on somatic cell hybrids capable of complementing the hypersensitivity of irs1 cells to the DNA interstrand crosslinking agent mitomycin C (MMC) ([@R16]; Thacker et al., 1995). The human cDNA was subsequently identified as a novel gene with considerable homology on the protein level to the RAD51 recombinase ([@R20]). The single protein coding human mRNA transcript (XRCC2--201), with a length of 3067 bp, has three coding exons (for a protein of 280 a.a.) arranged as shown below:

Description {#S7}
-----------

The human XRCC2 gene locus is 29.66 kb in length.

Transcription {#S8}
-------------

The single full-length transcript for human XRCC2 is 3,067 bp and there are no additional confirmed protein coding variants known (<http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000196584;r=7:152644779-152676165>).

Protein {#S9}
=======

Note {#S10}
----

The five somatic mammalian RAD51 paralogs, RAD51B, RAD51C, RAD51D, XRCC2 and XRCC3, form two prominent paralog-only protein complexes. These are the RAD51B-RAD51CRAD51D-XRCC2 (**BCDX2**) and RAD51CXRCC3 (**CX3**) complexes ([@R21]; [@R24]). RAD51C, which like XRCC2 is a FA protein, is the only member of both complexes. As demonstrated using a yeast 2-hybrid assay, XRCC2 directly binds RAD51D within the BCDX2 complex ([@R37]). Further, experiments with purified proteins expressed in insect cells indicate that RAD51D bridges RAD51C and XRCC2 together ([@R37]). The RNF138 E3 ubiquitin ligase appears to regulate the interaction of RAD51D with XRCC2 by ubiquitinating RAD51D and promoting ubiquitin-mediated degradation of this RAD51 paralog ([@R46]). XRCC2 itself regulates the abundance of the BCDX2 complex, since the RAD51B, RAD51C and RAD51D proteins display decreased stability in the absence of XRCC2 ([@R31]).

Other proteins, including RAD51 ([@R35]) and HELQ, directly interact with the assembled BCDX2 complex ([@R1]; [@R41]). It has also been reported that the BLM helicase interacts with the RAD51DXRCC2 complex via direct binding to RAD51D ([@R2]).

XRCC2 is essential for normal development in mice, as disruption of the Xrcc2 gene results in embryonic lethality ranging from mid-gestation to birth ([@R9]).

### Description {#S11}

While each of the five somatic RAD51 paralogs in humans has a somewhat similar size as RAD51, the paralogs show relatively low homology to RAD51. Specifically, the human XRCC2 protein has a size of 34 kD while human RAD51 has a molecular mass of 37 kD; human XRCC2 is 20% identical to human RAD51 at the amino acid level ([@R20]).

Still, each of the RAD51 paralogs, including XRCC2, shares Walker A and Walker B ATPase motifs with RAD51. The Walker A and Walker B motifs in human XRCC2 are present at a.a. 48--55 and 145--149, respectively ([@R25]), as shown below. No other functional domains have been identified in XRCC2.

### Expression {#S12}

According to the Human Protein Atlas (online), XRCC2 mRNA is expressed in cell lines representing a variety of tissue types, including the brain, skin, myeloid and lymphoid compartments, lung, breast and kidney.

The transcription factors MYC and ZNF281 bind to the XRCC2 promoter ([@R22]; [@R34]).

Further, it has been demonstrated that ZNF281 positively regulates XRCC2 expression ([@R34]).

Additionally, EZH2, a subunit of the PRC2 transcriptional repressor complex, may have a role in downregulating XRCC2 expression, as increased expression of EZH2 in breast cancer cells is associated with epigenetic repression of XRCC2 and other RAD51 paralogs ([@R48]).

### Localisation {#S13}

Consistent with its role in DNA repair, XRCC2 is a nuclear protein ([@R28]). When assayed by immunofluorescence microscopy and chromatin immunoprecipitation, XRCC2 localizes to engineered DNA double-strand breaks (DSBs) in nuclei ([@R35]). RAD51C also colocalizes with γ-H2AX in nuclear foci induced by etoposide ([@R35]). Aside of its nuclear localization, XRCC2 also localizes to centrosomes within the cytoplasm ([@R4]).

### Function {#S14}

Each of the five somatic RAD51 paralogs, including XRCC2, is required for DNA repair by homologous recombination (HR) ([@R14]; [@R42]). However, the role of XRCC2 and other RAD51 paralogs in promoting HR is less well understood than that of RAD51, which is the main mammalian recombinase. Still, molecular details concerning the role of XRCC2 in HR are emerging. For example, XRCC2 and other RAD51 paralogs appear to act upstream of RAD51 and regulate its assembly into nuclear foci ([@R6]; [@R31]; [@R32]; [@R42]). Further, purified XRCC2 can stimulate the ATPase activity of RAD51, thereby promoting the stability of the RAD51 oligomer and enhancing RAD51-dependent strand exchange during HR ([@R40]). While it is currently unclear whether this function of XRCC2 occurs within the context of the BCDX2 complex, the presence of XRCC2 favors short-tract gene conversion over long-tract gene conversion ([@R26]). Interestingly, work in Arabidopsis thaliana has demonstrated the existence of a RAD51-independent single-strand annealing (SSA) mechanism involving XRCC2, RAD51B and RAD51D ([@R38]); like HR, SSA is also a homology-dependent form of DNA repair. XRCC2 could also play a more direct role in HR than what is described above, since purified XRCC2 and RAD51D can stimulate homologous pairing of single-strand DNA with double-strand DNA in vitro ([@R18]).

Additional data suggests that XRCC2 functions in HR in the context of the previously mentioned BCDX2 protein complex. The fact that the BCDX2 complex binds Holliday junctions in vitro ([@R47]) supports this possibility. BRCA2, which also regulates the assembly of RAD51 foci, appears to be epistatic with the BCDX2 complex in mediating HR ([@R6]).

The BCDX2 complex also binds to replication forks in vitro ([@R47]). In support of a function in rescuing stalled or collapsed replication forks, XRCC2-deficient cells display compromised replication fork dynamics ([@R8]). This is consistent with the fact that HR is known to function in promoting the stability and rescue of arrested replication forks ([@R17]).

As a mediator of HR, XRCC2 also suppresses spontaneous chromosome abnormalities including breaks, deletions and translocations ([@R7]; [@R42]).

Also, related to its function in HR, XRCC2-deficient cells are hypersensitive to a variety of DNA damaging agents that directly or indirectly yield DNA double-strand breaks, including ionizing radiation, DNA interstrand crosslinking agents such as mitomycin C (MMC) and cisplatin, aldehydes, tirapazamine and temozolomide ([@R11]; [@R15]; [@R31]; [@R36]; [@R49]). Another function of XRCC2 that is potentially related to HR is in promoting accurate chromosome segregation and preventing mitotic catastrophe ([@R4]; Daboussi et al., 2005; [@R12]). However, it has been reported that XRCC2 localizes to centrosomes and it is possible that polyploidy or aneuploidy observed in XRCC2-deficient cells is associated with supernumerary centrosomes rather than a DNA repair defect ([@R4]; Daboussi et al., 2005; [@R12]).

Associated with its function in HR, XRCC2 also plays an essential role in promoting normal development ([@R9]). This includes a function in promoting normal lymphocyte development ([@R3]). Also, XRCC2 promotes survival of proliferating neural precursors in vivo ([@R29]).

### Homology {#S15}

Based on HomoloGene (NCBI), the following are homologs of the human XRCC2 gene (NP_005422.1, 280 a.a.):

Chimpanzee (Pan troglodytes) XP_001140134.1, 280 a.a.

Rhesus monkey (Macaca mulatta) XP_001108141.1, 280 a.a.

Dog (Canis lupus familiaris) XP_532771.3, 279 a.a.

Cattle (Bos taurus) NP_001095824.1, 280 a.a.

Mouse (Mus musculus) NP_065595.2, 278 a.a.

Rat (Rattus norvegicus) NP_001102685.1, 278 a.a.

Chicken (Gallus gallus) XP_418543.3, 278 a.a.

Tropical Clawed Frog (Xenopus tropicalis) XP_002932541.2, 282 a.a.

Mutations {#S16}
=========

Note {#S17}
----

Generally, germ-line alterations in XRCC2 are quite rare. In the largest study to date, of 13,087 breast cancer and 5,488 control cases from the UK, a total of 11 truncating and 32 rare missense variants were found ([@R10]). A recent study functionally characterized breast cancer-associated variants and found that each of the truncating or frameshift variants displayed compromised activity, while most of the missense variants tested displayed a minor change or no change in activity ([@R13]). Notably, a bi-allelic germ-line nonsense mutation in XRCC2 c.643C\>T encoding p.R215X is causative for the U complementation group of Fanconi anemia, FA-U ([@R31]; [@R39]).

XRCC2 was initially published as a low-risk breast cancer susceptibility gene, similar to other late FA genes such as BRCA1, BRCA2, PALB2 and RAD51C ([@R30]). However, subsequent studies could not confirm these findings and also presented data that the initial missense classification based on bioinformatic prediction tools was not correct (see below -\> Breast Cancer) ([@R10]; Hilbers et al., 2012; [@R33]).

### Epigenetics {#S18}

Increased levels of the PRC2 subunit, EZH2, leads to epigenetic repression of XRCC2 in breast cancer cells ([@R48]). Additionally, miR-7 interacts with XRCC2 mRNA in colorectal cancer cells; overexpression of miR-7 reduces XRCC2 promoter activity ([@R45]). Interestingly, XRCC2 promoter activity seems to be highly up-regulated in nearly all types of cancers ([@R5]).

Implicated in {#S19}
=============

Fanconi Anemia (FA) {#S20}
-------------------

### Note {#S21}

Germ-line bi-allelic and heterozygous mutations of XRCC2 (FANCU) are associated with different outcomes. Bi-allelic inactivating mutation of XRCC2 results in the FA-U subtype, while heterozygous inheritance of pathogenic XRCC2 mutations might increase the lifetime risk of germ-line mutation carriers for developing breast cancer.

### Disease {#S22}

Using whole exome sequencing, bi-allelic mutations in RAD51C were found in a 2.5 year old boy born to healthy Saudi first cousins with a spectrum of severe congenital anomalies suggestive of FA. These included microcephaly, facial palsy, a lack of thumbs, short stature and an ectopic left kidney ([@R39]). Importantly, biallelic loss-of-function mutations were detected in two other genes, MTBP and RGS3, in addition to XRCC2 ([@R39]). The authors scrutinized these genes with bi-allelic mutations, since this inheritance pattern is typical of FA. XRCC2 emerged as a candidate FA gene, in part because another RAD51 paralog, RAD51C, had previously been identified as a FA gene ([@R44]). However, as loss-of-function mutations were present in other genes, XRCC2 could not be reliably established as causative for the clinical phenotype in this initial study. A subsequent study demonstrated that XRCC2 (FANCU) is indeed the 20^th^ FA gene based on the correction, following expression of XRCC2, of cellular phenotypes that are characteristic of FA cells ([@R31]). These phenotypes included complementation of cellular hypersensitivity to MMC, correction of MMC-induced chromosome aberrations (total aberrations including breaks, gaps, radial and ring chromosomes, and number of radial chromosomes specifically), and MMC-induced cell cycle accumulation in G2-M ([@R31]). However, the patient had normal blood counts and had not displayed cancer through age 7 ([@R31]; [@R39]).

To date, 22 FA or FA-like genes have been identified ([@R27]). FA genes are autosomal recessive tumor suppressor genes, except for the X-linked FANCB and the autosomal dominant RAD51 (FANCR). The monoubiquitination of the FANCD2/FANCI protein dimer is the central step in the FA pathway. FANC -A, -B, -C -E, -F, CC: TXT: -G ID: 295\>, -L, -M, UBE2T (FANC-T) are early (or upstream) FA genes, since loss of function mutations in any of these genes results in defective monoubiquitination of FANCD2/I ([@R23]; [@R27]). Late/downstream FA genes, which are associated with normal monoubiquitination of FANCD2 and FANCI when mutated include: BRCA2 (FANCD1), BRIP1 (FANCJ), PALB2 (FANCN), RAD51C (FANCO), RAD51 (FANCR), BRCA1 (FANCS), XRCC2 (FANCU), MAD2L2 (FANCV/polTheta) and RFWD3 (FANCW). Typical of late/downstream FA genes, FA-U cells display defective assembly of RAD51 foci in response to DNA damage ([@R31]).

The vast majority of FA patients have bi-allelic mutations in the upstream FA genes, notably FANCA, FANCC and FANCG, and display clinical features characteristic of FA. These include progressive bone marrow failure around 7.6 years of age, a variety of congenital anomalies, and a predisposition to acute myeloid leukemia as well as various solid tumors that occur in the second and third decade of life ([@R19]). Microcephaly, short stature, skin pigmentation defects, hypogonadism, and radial ray anomalies, many of which were observed in the single FA-U patient identified until present, are among the congenital anomalies that are often observed. Endocrine abnormalities are also seen in a significant number of FA patients (Rose et al., 2012).

Certain other FA complementation groups such as FA-O, defined by RAD51C (FANCO) mutations, and FA-R, defined by heterozygous dominant-negative RAD51 (FANCR) mutation, have been designated atypical FA (or FA-like) because of the absence of bone marrow failure and no increased incidences of cancer ([@R31]). However, bone marrow failure and cancer are not always observed for every patient in each FA complementation group and the single FA-U patient identified so far has not reached the age at which these features are frequently observed ([@R19]). Therefore it is not yet clear whether or not patients with germ-line bi-allelic defects in XRCC2 represent atypical FA.

Breast Cancer {#S23}
-------------

### Disease {#S24}

In a collaborative exome-sequencing study involving patients from the Netherlands, Spain and Australia, Park et al. identified 6 out of 1308 patients with early-onset breast cancer as having likely deleterious mutations in XRCC2, while none of the 1,120 controls carried such a mutation. Two of the six mutations were frameshift mutations (p.Arg17\* and p.Cys217\*) and 4 of the 6 were missense alterations with single a.a. exchanges that were predicted by three algorithms to be associated with a loss-of-function ([@R30]). As the frequency at which these variants occurred in breast cancer patients, as compared to controls, was statistically significant, XRCC2 was identified by the authors as a low frequency breast cancer susceptibility gene.

However, no other study so far has confirmed mutation of XRCC2 as a significant cause of inherited breast cancer ([@R13]; Hilbers et al., 2012; [@R33]). For example, Hilbers et al. analysed the coding region of 3548 non-BRCA1/2 familial breast cancer cases and 1435 healthy controls (Hilbers et al., 2012). In the patient group, they detected only one patient with a protein truncation mutation and 20 patients with missense alterations, as compared to nine controls with missense variants. Importantly, in 2016, Hilbers et al. functionally analyzed all nonsynonymous coding variants from the two major studies published in 2012 (Hilbers et al., 2012; [@R30]). Out of 24 missense alterations, only four variants had a reduced functional activity with 50--75% rescue in two out of three assays ([@R13]).

Finally, Decker et al. sequenced the XRCC2 coding region of 13,087 breast cancer patients and 5488 healthy controls from the UK ([@R10]). Only 13 carriers of truncating XRCC2 variants were found, nine in breast cancer patients and four in controls. There were also no statistical differences for 32 rare missense variants between the patient and control groups. Thus these authors concluded that truncating/loss-of-function mutations in XRCC2 are not associated with an increased risk of breast cancer ([@R10]), and therefore germ-line mutation of XRCC2 is not a major cause of inherited breast cancer ([@R10]; Hilbers et al., 2012).

### Prognosis {#S25}

Because XRCC2 has an important role in HR, it is likely that tumors with loss-of-function of XRCC2 may be particularly responsive to poly (ADP-ribose) polymerase (PARP) inhibitors. In support of this possibility, FA cells from the FANCU complementation group, which have biallelic mutation of XRCC2, have increased sensitivity to the PARP inhibitor olaparib, as compared to complemented cells ([@R31]). Thus, identification of breast cancer patients, and perhaps other cancer patients, with deleterious somatic variants of XRCC2 may be a basis for such personalized treatments.
